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Abstract
Background: Traditional protease inhibitors target the active
site of the enzyme. However, since most proteases act on multiple
substrates, even the most specific protease inhibitors will affect the
levels of a number of different proteins. However, if substrate-
targeted inhibitors could be developed, much higher levels of
specificity could be achieved. In theory, compounds that bind the
cleavage site of a particular substrate could block its interaction
with a protease without having any effect on the processing of
other substrates of that protease.
Results : A model system is presented that demonstrates the
feasibility of substrate-targeted inhibition of proteolysis. A peptide
selected genetically to bind a 14-residue epitope that encompasses
the cleavage site of human pro-IL-1L was shown to inhibit
interleukin-converting enzyme (ICE)-mediated proteolysis of
model substrates containing the 14-mer target sequence. However,
the peptide had no effect on the cleavage of other ICE substrates
with different amino acids flanking the minimal cleavage site.
Conclusions: This study demonstrates the feasibility of sub-
strate-targeted inhibition of proteolysis. More potent compounds
must be developed before substrate-targeted inhibitors can be used
routinely. Nonetheless, this novel strategy for protease inhibition
seems promising for the development of extremely selective
molecules with which to manipulate the maturation of many
important pro-hormones, -cytokines and -proteins. ß 2001 Pub-
lished by Elsevier Science Ltd.
Keywords: Cleavage site ; Protease inhibitor; Sequence-speci¢c
proteolysis ; Substrate-targeted inhibitor
1. Introduction
A major goal in chemical biology is to develop synthetic
molecules capable of manipulating particular biological
pathways. A particularly important target in this regard
is the post-translational modi¢cation of proteins, since
phosphorylation, ubiquitinylation, glycosylation, proteoly-
sis and a variety of other events have enormous e¡ects on
the activities and levels of many critical regulatory factors.
A major issue in this area is speci¢city. For example, while
many protein kinase inhibitors are known, a traditionally
di⁄cult issue in this ¢eld has been to obtain compounds
that are highly selective for a given kinase, since the active
sites of many of these enzymes are quite similar. This often
requires extensive optimization or multiple cycles of com-
binatorial chemistry. Furthermore, even in the case where
an inhibitor has extremely high speci¢city for a given en-
zyme, it will nonetheless a¡ect more than one event. This
is because the vast majority of enzymes that mediate the
post-translational modi¢cation of other proteins operate
on multiple substrates. This fact places a fundamental lim-
it on the biological speci¢city that one can achieve using
an enzyme-targeted inhibitor.
An alternative strategy would be to manipulate the
post-translational modi¢cation of proteins with com-
pounds that recognize the substrate rather than the en-
zyme. Most proteases, protein kinases, etc. have relatively
small recognition sequences. Thus, if one could design
molecules able to recognize not only these core sites, but
£anking residues as well, it might be possible to employ
these species as ‘epitope protecting groups’ capable of
shielding a speci¢c protein from a given modi¢cation en-
zyme without a¡ecting the processing of other proteins by
the same enzyme. This concept is illustrated in Fig. 1 in
the context of a substrate-speci¢c protease inhibitor.
The challenge in implementing this strategy is to identify
molecules capable of recognizing linear epitopes in the
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target protein that include the processing site. While this
can be done using monoclonal antibodies, there is little
literature regarding peptide epitope recognition by rela-
tively low molecular weight, synthetic molecules [1^5], par-
ticularly in aqueous solution [6,7]. Recently however, we
introduced a two-hybrid-like genetic selection system that
may be generally useful for the selection of epitope-bind-
ing peptides [8]. This assay, modeled after a scheme orig-
inally developed by Hu and co-workers for the study of
leucine zipper interactions [9,10], involves reconstitution of
lambda Repressor activity via a peptide^peptide interac-
tion. Speci¢cally, the native C-terminal dimerization do-
main of lambda Repressor is replaced by either a peptide
library or a speci¢c target epitope. In the absence of di-
merization, lambda Repressor DNA-binding domain
(DBD) does not bind tightly to operator sequences or
repress transcription e⁄ciently. Two di¡erent compatible
plasmids that express these fusion proteins are trans-
formed into Escherichia coli and these cells are then chal-
lenged with lethal levels of lambda phage. Cells that sur-
vive the phage challenge generally have reconstituted
Repressor activity. After the removal of undesired ‘false
positives’ (such as library-encoded homooligomeric pep-
tides [11]) library-encoded peptides (LEPs) that bind to
the target epitope and thus reconstitute Repressor DBD
dimerization, can be identi¢ed.
In a previous report, we identi¢ed a 15-residue LEP able
to bind a 14-amino acid epitope nearly identical to a se-
quence found in human pro-interleukin-1L (IL-1L) [8]. IL-
1L is a cytokine that is secreted primarily by activated
monocytes and macrophages in response to infection or
injury [12]. Like many cytokines and hormones, human
IL-1L is translated as an inactive precursor that must be
matured proteolytically to generate the bioactive species.
This cleavage reaction, which transforms a 31.5-kDa pro-
protein to the 17-kDa mature cytokine, is mediated by an
interleukin-converting enzyme (ICE; also know as caspase
1) [13,14]. Given the critical role played by IL-1L in in-
£ammation as well as other biological processes, there has
been tremendous interest in the development of ICE in-
hibitors to block maturation of the pro-hormone. How-
ever, ICE has a number of other known substrates, includ-
ing IL-18 [15,16] and IFN-Q-inducing factor [17]. ICE also
autocatalyzes its own conversion from a zymogen to the
heterodimeric, active protease [18,19]. Thus, the ICE-
mediated cleavage of pro-IL-1L seemed an interesting sys-
tem in which to probe the feasibility of substrate-targeted
inhibition of post-translational modi¢cation. We demon-
strate here that a LEP isolated in the genetic screen is
indeed capable of inhibiting ICE-mediated cleavage of
model substrates containing the human pro-IL-1L process-
ing site. The same LEP had no a¡ect on the ICE-mediated
cleavage of a substrate containing a cleavage site corre-
sponding to that of the ICE zymogen. This validates the
general idea that relatively low molecular weight, synthe-
sizable molecules can be employed as substrate-speci¢c
manipulators of the post-translational modi¢cation of
proteins.
2. Results
As discussed above, we recently described a simple ge-
netic selection system that allows peptide libraries to be
screened for molecules able to bind protein epitopes (i.e.,
other peptides) with excellent speci¢city [8]. One such
complex discovered using this system was comprised of a
15-amino acid residue LEP KARKEAELAAATAEQ
(called LEPB since it was the second of four isolated
from a genetically encoded library) and a 14-amino acid
target epitope NEAYVHDGPVRSLN. This epitope was
designated ICS, since it is almost identical to residues 110^
123 of the immature form of human IL-1L, which includes
the ICE cleavage site (after Asp116). To test the concept
of substrate-targeted protease inhibition, LEPB was as-
sayed for its ability to block ICE-mediated cleavage of
the ICS epitope and its speci¢city for this sequence relative
to other ICE substrates.
To carry out this experiment, two model protein sub-
strates were made using standard molecular cloning and
protein expression techniques. One, called Matched, in-
cludes an N-terminal glutathione S-transferase (GST) pro-
tein connected to a C-terminal green £uorescent protein
(GFP) protein via a linker that includes the ICS
(NEAYVHDGPVRSLN). The second, called Mismatched,
is comprised of an N-terminal GST linked to a C-terminal
maltose-binding protein (MBP) via a linker that includes
the site in pro-ICE that undergoes cleavage during zym-
ogen maturation [7], GVVWFKDSVGVSGN. The Asp
residue adjacent to the ICE cleavage site in each sequence
is highlighted in bold and underlined. This zymogen se-
quence has little homology with ICS other than the Asp
residue recognized by the enzyme.
The Matched and Mismatched substrates were mixed in
equimolar amounts in the same tube with or without
LEPB, then puri¢ed ICE enzyme was added. Fig. 2 shows
the results of this experiment. The apparent molecular
Fig. 1. Schematic representation of the two types of proteolysis inhibi-
tors discussed in this study. Traditional protease inhibitors are targeted
to the enzyme itself (usually the active site). A substrate-targeted inhibi-
tor would bind an epitope in the substrate that includes the site of enzy-
matic cleavage.
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mass of the Matched substrate is approximately 60 kDa
and that of the Mismatched protein is 85 kDa, as shown in
lane 1. Lane 2 shows the result of adding puri¢ed ICE to a
mixture of the two substrates in the absence of inhibitor.
As expected, proteolysis of the W60 kDa Matched protein
yielded GST protein (27 kDa) and GFP protein (29 kDa)
containing fragments. ICE-mediated cleavage of Mis-
matched produced GST protein (27 kDa) and MBP (50
kDa) containing fragments. Both substrates were pro-
cessed with approximately equal e⁄ciency.
Addition of synthetic LEPB to the reaction had mark-
edly di¡erent e¡ects on Matched and Mismatched cleav-
age. In the latter case, LEPB had no inhibitory e¡ect on
proteolysis even at concentrations up to 1 mM (Fig. 2,
lanes 3^8). However, for the Matched protein substrate,
signi¢cant inhibition of cleavage was observed starting at
50 WM LEPB and reaching saturation around 250 WM.
This is most evident by inspection of the Matched band
intensity at increasing LEPB concentrations and the con-
comitant decrease in the band corresponding to the GFP
fragment-containing product. At 250 WM LEPB, only ap-
proximately 20% of the Matched protein substrate was
cleaved under the conditions employed, compared with
approximately 90% cleavage in the absence of the peptide.
This di¡erential rate of cleavage can also be observed in a
time course experiment (Fig. 4). The data in Fig. 4 reiter-
ate that the two substrates are processed with similar ki-
netics by ICE in the absence of inhibitor molecules.
A 19-amino acid peptide, GGWSGGCGRTSAVS-
SASFP, selected randomly from the library, had no e¡ect
on the ICE-mediated cleavage of either substrate at con-
centrations ranging from 25 WM to 1 mM (Fig. 3). Finally,
a 15-amino acid peptide AEAALARKETAKEQA, which
is a randomized version of LEPB, also had no e¡ect on
ICE-mediated cleavage of either the Matched or Mis-
matched substrate at concentrations up to 1 mM (data
not shown). These results argue that the 15-residue
LEPB is acting as a sequence-speci¢c, substrate-targeted
inhibitor of the Matched processing by ICE.
The only data that seemed at odds with the proposed
mechanism of action of LEPB was the IC50 of approxi-
mately 100^150 WM. Previously, we had reported that the
KD of the LEPB/ICS complex is approximately 2 WM [8].
If LEPB inhibition of Matched cleavage indeed was the
result of the peptide binding the cleavage site and shielding
Fig. 2. Substrate-speci¢c inhibition of ICE-mediated proteolysis by
LEPB. Varying concentrations of LEPB were included in a reaction
containing two model substrates, both of which are cleaved by ICE.
One (Matched) contains the pro-IL-1L cleavage site that LEPB was
selected to bind. The other (Mismatched) contains the pro-ICE cleavage
site. Matched = GSTNEAYVHDGPVRSLNGFP ; Mismatched = GST-
GVVWFKDSVGVSGNMBP. The bands present in the ¢rst lane other
than those corresponding to Matched and Mismatched are due to low
levels of proteolytic fragments (from the E. coli extract) in the puri¢ed
preparations. LEPB = KARKKEAELAAATAEQ.
Fig. 4. Time course for the ICE-mediated proteolysis of Matched and
Mismatched in the presence or absence of 250 WM LEPB or the 19-mer
peptide.
Fig. 3. A control peptide not selected to bind either substrate does not
inhibit ICE-mediated proteolysis. A 19-amino acid peptide, picked ran-
domly from the library from which LEPB was isolated, was employed
in place of LEPB in the same experiment described in Fig. 2. 19-
mer = GGWSGGCGRTSAVSSASFP.
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it from ICE, then one would expect that the IC50 would
roughly mirror the KD of the peptide^peptide complex.
The bu¡er conditions and temperature employed in the
protease assay and the previous KD measurement were
not identical and di¡erent fusion proteins were employed
in each study. However, this seemed a rather large di¡er-
ence to explain away based simply on these di¡erences.
To probe this issue in more detail, we employed a £uo-
rescence polarization experiment [20] to measure directly
the KD of the LEPB^ICS complex under the conditions of
the proteolysis assay. LEPB was synthesized with an N-
terminal £uorescein label and this molecule (20 nM) was
then titrated with an ICS-containing fusion protein (GST^
ICS) in the cavity of a Beacon 2000 £uorescence polar-
ization instrument. The data obtained (average of three
experiments) are shown in Fig. 5. The readings at very
high GST^ICS concentrations were less reproducible
than the values obtained at lower concentrations, possibly
due to light scattering, so a speci¢c dissociation constant
cannot be gleaned from these data. However, it is clear
that the KD is much higher than the 2 WM measured pre-
viously and appears to be somewhere in the range of 70^
150 WM, more consistent with the results of the ICE inhi-
bition assay. Similar experiments conducted at di¡erent
peptide concentrations gave identical results (data not
shown), indicating that the conditions chosen represented
equilibrium binding. Furthermore, the use of LEPB-re-
lated peptides that also contained several residues present
in the genetically selected fusion protein (i.e., the ‘hit’ in
the original assay) also provided essentially identical re-
sults (data not shown), arguing that context e¡ects are
not terribly important. Based on these data, we therefore
conclude that all of the available data are consistent with
LEPB acting as a substrate-targeted inhibitor of proteol-
ysis that acts through a sequestration mechanism.
3. Discussion
As discussed in Section 1, enzyme-targeted inhibitors of
protein-modifying factors have an intrinsic limit in their
speci¢city. This is a simple consequence of the fact that
most modifying enzymes have multiple substrates. All of
these processing events will be a¡ected to some extent by
an enzyme-targeted molecule. Substrate-targeted inhibi-
tors, on the other hand, have the potential for much high-
er speci¢city since they could, in theory, retard the rate of
a single processing event without a¡ecting other reactions
mediated by the same enzyme. Another application would
be to block a processing event for which the enzyme is
unknown or which can be mediated by more than one
enzyme. Substrate-targeted inhibitors could be extremely
useful tools for probing the biological manifestation(s) of
a particular post-translational modi¢cation event. It is also
possible that the same strategy could have therapeutic ap-
plications, for example if a single enzyme mediated both
‘good’ and ‘bad’ reactions from the standpoint of a de-
sired therapeutic outcome.
To the best of our knowledge, this study provides the
¢rst example of substrate-targeted inhibition of proteolysis
by a synthetic molecule (see [21] for the use of antibodies
in this type of application). A peptide selected genetically
to bind a linear epitope almost identical to human pro-IL-
1L [8] was indeed able to inhibit ICE-mediated proteolysis
of the cleavage site contained in this sequence without
a¡ecting another ICE-mediated reaction in the same
tube. As expected therefore, the epitope-binding peptide
was able to use the unique information inherent in the
di¡erent sequences £anking the site recognized by the en-
zyme to distinguish between substrates. Various control
peptides not selected to bind the cleavage site had no e¡ect
on any of the reactions studied. If this approach proves to
be general, and more e⁄cient inhibitors can be developed,
this technique may be useful in providing the functional
equivalent of a conditional knockout of a given polypep-
tide if that species must be matured proteolytically. It
should also be possible to extend this substrate-targeted
inhibition approach to other types of protein-modifying
events. Indeed, Nestler and co-workers have previously
used epitope-targeted ‘molecular forceps’ to inhibit farne-
sylation of fusion proteins containing a peptide represent-
ing the C-terminus of Ras [7]. Other than the experiments
reported here, this is the only other example of a synthetic
substrate-targeted inhibitor of which we are aware.
While we are hopeful that the substrate-targeted inhib-
itor approach can eventually be developed into a useful
general tool for the manipulation of protein-modi¢cation
events, several important challenges must be met before
this strategy achieves practical utility. Of course, peptides
Fig. 5. Association of LEPB (20 nM) and a GST^ICS fusion protein
monitored by £uorescence polarization. The data indicate that the KD
of the LEPB^ICS complex under these conditions is on the order of 70^
120 WM.
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such as LEPB are unlikely to be pharmaceutically useful
reagents, but given impressive recent advances in methods
to carry cell-impermeable molecules across membranes
[22^26], they might be useful research tools. A more im-
portant current limitation is the modest a⁄nities that the
currently available epitope-binding peptides have for their
targets. The LEPB molecule employed in this study exhib-
ited an IC50 of approximately 70^150 WM under the con-
ditions employed. The binding experiments shown in Fig.
5 indicate that this is most likely a reasonable re£ection of
its a⁄nity for the target epitope under these conditions.
Clearly, this is insu⁄cient for LEPB to be employed in a
practical sense, for example in a cell culture experiment, as
an inhibitor of IL-1L maturation. Since only a few epitope
targets have been examined to date, it is too early to say
whether this a⁄nity will prove to be typical of peptide^
peptide complexes isolated using the Repressor reconstitu-
tion strategy or any other assay. But if this is the case, an
important immediate goal will be to devise e⁄cient, rela-
tively high-throughput strategies by which to elaborate
these molecules into high-a⁄nity epitope binders without
sacri¢cing synthetic expediency. For example, one
straightforward approach would be to explore second-gen-
eration libraries comprised of peptides that resemble the
initial hit. These could be screened by phage display [30]
or some other in vitro technique that would allow the
stringency of the binding conditions to be controlled. We
are in the process of exploring several strategies to obtain
high-a⁄nity epitope-binding compounds.
It is worthwhile to comment here on why the apparent
KD of the LEPB^ICS complex seen here is signi¢cantly
di¡erent than that reported previously (W2 WM) [8]. While
di¡erences in conditions between the two experiments and
the local context of the peptide play a role, we speculate
that the nature of the assay used previously may have been
even more of an issue. In that work, a GST ‘pull-down’
assay was employed in which various concentrations of
GST^ICS were incubated with an extract containing over-
expressed Repressor DBD-LEPB. The extent of complex
formation was evaluated at each GST^ICS concentration
by precipitation with glutathione-agarose beads followed
by SDS^PAGE and Western blotting. GST is a homo-
dimer [27] and thus displayed the ICS peptide as such.
Furthermore, while the Repressor DBD is not a stable
dimer, it does have some residual self-associating capabil-
ity, particularly in extracts where it has been overex-
pressed. Thus, while the value reported for the KD of
the Repressor LEPB^GST^ICS complex is correct, it
may not accurately re£ect the true LEPB^ICS KD due to
avidity e¡ects (i.e., the contribution of a 2:2 complex).
While this study and that of Nestler and colleagues [7]
employed peptides as epitope-binding molecules, there is
no reason to believe that appropriate non-peptidic mole-
cules could not ful¢ll the same role. While it is unlikely
that a truly small (6 500 Da) drug-like molecule could
recognize an extended linear epitope, non-peptidic oligo-
mers of some sort are more promising candidates. Such
molecules may or may not exhibit enhanced cell perme-
ability, but would at least be immune to proteases, an
important feature if they are to be used as tools for cell
culture or even in vivo experiments. Finally, it should be
pointed out that single chain antibodies [28] or epitope-
binding proteins based on alternative protein sca¡olds [29]
do have su⁄cient binding constants to be employed as
substrate-speci¢c manipulators of post-translational mod-
i¢cations. In cell culture experiments or even in transgenic
animals, these molecules could be used to elicit the desired
‘knockout’ e¡ect of a given event. However, such biolog-
ical approaches are less desirable than the use of synthetic
molecules since the latter can be applied at any time in the
course of an experiment, making manipulation of the sys-
tem far easier.
4. Signi¢cance
The feasibility of using epitope-binding compounds as
substrate-targeted inhibitors of proteolysis has been dem-
onstrated. While the peptide inhibitor in hand binds too
weakly to be of practical utility, this novel result indicates
a pathway for the future development of highly selective
manipulators of proteolytic maturation of pro-proteins as
well as other post-translational modi¢cations of proteins.
5. Materials and methods
The puri¢ed ICE enzyme was kindly provided by Dr. Nancy
Thornberry (Merck).
5.1. Peptide synthesis and labeling
All the peptides were synthesized using a Perkin-Elmer Synergy
solid-phase peptide synthesizer using Fmoc chemistry. The pep-
tides were cleaved from beads using tri£uoroacetic acid. The de-
sired peptides were puri¢ed by reverse-phase HPLC. Each peptide
was characterized by electrospray mass spectrometry and pro-
vided the anticipated molecular ion.
Fluorescein-labeled LEPB was made by treating 25 mg of the
beads on which the peptide was synthesized with excess piperidine
for 30 min at room temperature. After removing most of the
piperidine via syringe, 1 ml of carboxy£uorescein-N-hydroxysuc-
cinimidyl ester in DMF (20 mg/ml) was added to the slurry and
the resultant mixture was incubated at room temperature for 4 h.
After this time, the beads were washed extensively with DMF and
DMSO to remove excess starting material. The £uoresceinated
peptide was cleaved from beads with TFA, puri¢ed by reverse-
phase HPLC and characterized by mass spectrometry.
5.2. Construction of the GST^ICS expression vector (pGST^ICS)
Oligonucleotides encoding the peptide sequence NEAYVHD-
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GPVRSLNCIIHRD (amino acids present in the ICS are under-
lined) were inserted into pGEXcs digested with NcoI and BamHI.
After transformation of E. coli and puri¢cation of the plasmid by
standard methods, the construct was veri¢ed by DNA sequencing.
5.3. Construction of the expression vectors for the Matched and
Mismatched proteins (pMATCH and pMISMATCH)
Two oligos: 5P-CCGGGGGAACGAAGCATACGTACAC-
GACGGACCCGTAAGAAGCCTAAACGTA and 5P-CCGGT-
ACGTTTAGGCTTCTTACTGGTCCGTCGTGTACGTATGC-
TTCGTTCCC were annealed and ligated into the vector pGFPuv
(Clontech) that had been digested with restriction enzymes XmaI
and AgeI. The products were veri¢ed by DNA sequencing. A pair
of PCR primers was used to amplify the DNA fragment encoding
both the ICS peptide and the GFP protein. The PCR product
was digested with EcoRI and NcoRI restriction enzymes, gel-pu-
ri¢ed and ligated into vector pGEXcs digested with EcoRI and
NcoRI to provide pMATCHED. The construct was veri¢ed by
DNA sequencing.
To make pMISMATCHED, two oligos: 5P-TCGAGGGAG-
TCGTCTGGTTCAAAGACTCAGTCGGCGTCTCAGGGAA-
CGC and 5P-CATGGCGTTCCCTGAGACGCCGACTGAGT-
CTTTGAACCAGACGACTCCC were annealed and ligated
into the vector pGEXGGH digested with XhoI and NcoI. This
vector was subsequently digested with NcoI and SmaI. A PCR
product containing sequences encoding the MBP was then cut
with the same enzymes and inserted into the NcoI/SmaI-cut vec-
tor to provide pMISMATCHED. This construct was veri¢ed by
DNA sequencing.
5.4. Puri¢cation of GST fusion proteins
The pGST^ICS, pMATCHED or pMISMATCHED plasmids
were transformed into BL21 (DE3) competent cells and plated on
a LB plate supplemented with ampicillin, and grown at 37‡C
overnight. A single colony was inoculated into 2 ml of LB me-
dium supplemented with ampicillin. The 2-ml culture was inocu-
lated into 50 ml of LB medium supplemented with ampicillin and
grown to saturation. The 50-ml culture was inoculated into 1 l of
LB medium with ampicillin and grown to an OD600 of 0.5. The
culture was induced with 0.5 mM IPTG and grown at 37‡C for
3 h. The cells were harvested by centrifugation at 3500 rpm for 15
min. The pellet was resuspended in 25 ml of PBS bu¡er solution
supplemented with protease inhibitor tablets (Boehringer Mann-
heim). The suspension was frozen with liquid nitrogen and stored
at 370‡C overnight. The suspension was thawed at room temper-
ature and subjected to sonication. The resulting mixture was cen-
trifuged at 12 000 rpm for 45 min. The supernatant was added to
1 ml of glutathione-fused beads and tumbled at 4‡C for 2 h. The
beads were centrifuged at 3000 rpm for 5 min, then washed three
times with PBS solution supplemented with 500 mM NaCl. The
beads were equilibrated with PBS and bound GST fusion pro-
teins were released by the addition of 10 mM of reduced gluta-
thione in TE bu¡er. The eluted sample was dialyzed against PBS
at 4‡C to remove the reduced glutathione.
5.5. KD measurement by £uorescence polarization experiment
A series of 200-Wl solutions was set up with HEPES bu¡er (10
mM, pH 7.5), 10% sucrose, 2 Wg of Melittin £uoresceinated
LEPB (20 nM) and GST^ICS protein (0, 10 WM, 25 WM, 50
WM, 100 WM and 200 WM). The solutions were allowed to
come to equilibrium by incubating at room temperature for 20
min. The samples were then placed into the cavity of a £uores-
cence spectrometer equipped to measure anisotropy (PanVera
Beacon 2000). The polarization of the emitted light was recorded.
Three identical experiments were conducted and the values were
averaged.
5.6. Proteolysis inhibition assay
10 WM of Matched protein, 10 WM of Mismatched protein, 10%
sucrose and HEPES bu¡er (10 mM, pH 7.5) were mixed with 0^
1000 WM LEPB (Fig. 1) or 0^1000 WM 19-mer control peptide
(Fig. 2) in a total volume of 30 Wl. The mixture was left at 4‡C for
30 min, then allowed to warm up to room temperature for 5 min.
To the reaction mixture was added ICE (540 Units). After a
2-min incubation at 25‡C, the reactions were stopped with 4U
SDS-containing dye solution. The reaction mixtures were then
analyzed by SDS^PAGE (Fig. 1). The time course experiment
employed the same general protocol, but employed 250 WM of
LEPB or the control 19-mer. After quenching at the appropriate
times with denaturing gel-loading bu¡er, the reaction mixtures
were analyzed by SDS^PAGE and staining with Coomassie
blue. The data shown in Fig. 4 were obtained by densitometric
scanning of the stained gels.
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